Physician profile
John Boyle
NPI 1225177009
$7,102.28
in general payments reported to CMS, 2019-2025
28 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $197 · 2021: $922 · 2022: $789 · 2023: $966 · 2024: $1,696 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,433.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,561.83 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $714.71 | 2019-2025 | Catalys System, Tecnis Simplicity, Tecnis Iol |
| Glaukos Corporation | $543.99 | 2019-2025 | Idosetr, Idose, Kxl System (Not Refurbished) |
| Tarsus Pharmaceuticals, INC. | $516.90 | 2024-2025 | Xdemvy |
| Rxsight INC | $411.32 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Ivantis, INC | $405.16 | 2021 | |
| Abbvie INC. | $327.04 | 2022-2025 | |
| Oyster Point Pharma, INC. | $324.08 | 2022-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $314.19 | 2022-2025 | Acthar |
| Dompe US, INC. | $233.84 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $227.01 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Carl Zeiss Meditec USA, INC. | $206.45 | 2021 | |
| Allergan, INC. | $196.28 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $180.60 | 2019-2023 | Cequa |
| Biotissue Holdings INC. | $149.64 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $114.49 | 2023-2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $113.00 | 2019-2022 | |
| Sight Sciences, INC. | $108.76 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Heidelberg Engineering, INC. | $71.60 | 2022 | |
| Aerie Pharmaceuticals, INC. | $68.28 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $66.86 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $61.87 | 2022 | |
| Harrow Eye, LLC | $47.43 | 2024 | Vevye |
| New World Medical,INC. | $37.22 | 2025 | Clearpath, Via360, Streamline |
| Coopervision INC. | $30.40 | 2022-2025 | Biofinity Contact Lens |
| Novartis Pharmaceuticals Corporation | $30.20 | 2023 | |
| Beaver-Visitec International, INC. | $24.90 | 2023 | |
| Ani Pharmaceuticals, INC. | $14.23 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.